Amyloidosis Treatment Market - Forecast(2024 - 2030)

Key Takeaways

• The market is estimated to grow at a CAGR of 7.1% owing to the rising prevalence of the disease among geriatric population.
• Companies are adopting various strategic alliances to expand in various regions. Investments in research have increased in order to develop treatment drugs for amyloidosis.
• Amyloidosis is of various types such as AA (Amyloid A), AL (Amyloid light chain), ATTR (Amyloid transthyretin) or transthyretin amyloidosis, and others.

Treatment - Segment Analysis

By treatment, chemotherapy is the major segment in this market with CAGR of 5.2%. This is because, it is one of the most effective forms of treatment opted for by many patients. Chemotherapy is usually administered by an intravenous tube or orally as a drug. Targeted therapy will have a higher growth rate in the coming years. Targeted therapies include, anti-angiogenesis therapy, monoclonal antibodies, and proteasome inhibitors.

Geography - Segment Analysis

North America is dominant in the market by geography and holds 35% of the Amyloidosis Treatment market share. This is owing to the release of pipeline drugs here, advanced treatment opportunities for people and the health care facilities availability here.

Drivers – Amyloidosis Treatment Market

·         Growing geriatric population and prevalence of amyloidosis in them

As per statistics on the American Society of Clinical Oncology, around 4000 people in U.S. develop amyloidosis each year and it is typically diagnosed among people aged 50-65 years. There are only a few cases of people in their late 20s being diagnosed with amyloidosis. Thus with a rise in elderly population, the amyloidosis treatment market will also grow.

·         Favorable investments in different countries

The governments of various countries are investing in their research & development for drugs and other treatment methods for amyloidosis. Some developed economies have advanced medical treatments and technologically advances diagnostics also. Thus with increased support from government or other authorizing bodies, the market in such regions will flourish.

Challenges – Amyloidosis Treatment Market

·         High cost of treatment and limited awareness

In some developing or underdeveloped nations, the market for amyloidosis will be constrained due to higher costs of healthcare as well as the limited awareness among the people here. However, government initiatives are increasing in such regions and these markets are said to have prospective growth.

Amyloidosis Treatment Industry Outlook

Research & development along with strategic alliances are some of the key strategies adopted by players in the Amylodosis Treatment market. Amylodosis Treatment Market top 10 companies are Prothena Corporation plc., Pfizer Inc., Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Celgene Corporation, Takeda Pharmaceutical Company Ltd., Johnson and Johnson Pvt. Ltd., GlaxoSmithKline plc, Alnylam Pharmaceuticals Inc., SOM Innovation Biotech S.L., AstraZeneca plc.

Amyloidosis Treatment Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Amyloidosis Treatment Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats.